Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.24 subject to Rule 16b-3
| 382550BR1 | 86.22 5.44 5.93% |
About 61% of 382550BR1's investor base is looking to short. The analysis of the overall prospects from investing in GT 525 15 JUL 31 suggests that many traders are, at the present time, alarmed. The current market sentiment, together with 382550BR1's historical and current headlines, can help investors time the market. In addition, many technical investors use GT 525 15 bond news signals to limit their universe of possible portfolio assets.
382550BR1 |
Filed transaction by Cumberland Pharmaceuticals Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
GT 525 15 Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 382550BR1 bond to make a market-neutral strategy. Peer analysis of 382550BR1 could also be used in its relative valuation, which is a method of valuing 382550BR1 by comparing valuation metrics with similar companies.
Peers
382550BR1 Related Equities
| EWCZ | European Wax | 1.35 | ||||
| GFF | Griffon | 0.95 | ||||
| JELD | Jeld Wen | 0.74 | ||||
| WEYS | Weyco | 0.22 | ||||
| CEIX | Consol Energy | 0.53 | ||||
| RBC | RBC Bearings | 1.34 |
Other Information on Investing in 382550BR1 Bond
382550BR1 financial ratios help investors to determine whether 382550BR1 Bond is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 382550BR1 with respect to the benefits of owning 382550BR1 security.